Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinoma.
Lin DF, Li HL, Liu T, Lv XF, Xie CM, Ou XM, Guan J, Zhang Y, Yan WB, He ML, Mao MY, Zhao X, Zhong LZ, Chen WH, Chen QY, Mai HQ, Peng RJ, Tian J, Tang LQ, Dong D. Lin DF, et al. Among authors: lv xf. J Natl Cancer Inst. 2024 Apr 19:djae081. doi: 10.1093/jnci/djae081. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38637942
Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT.
Xiao BB, Lin DF, Sun XS, Zhang X, Guo SS, Liu LT, Luo DH, Sun R, Wen YF, Li JB, Lv XF, Han LJ, Yuan L, Liu SL, Tang QN, Liang YJ, Li XY, Guo L, Chen QY, Fan W, Mai HQ, Tang LQ. Xiao BB, et al. Among authors: lv xf. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2586-2598. doi: 10.1007/s00259-020-05128-8. Epub 2021 Jan 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 33420610
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ. Yuan L, et al. Among authors: lv xf. Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x. Nat Commun. 2023. PMID: 37580352 Free PMC article. Clinical Trial.
Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control study.
Xiao BB, Chen QY, Sun XS, Li JB, Luo DH, Sun R, Lin DF, Zhang X, Fan W, Lv XF, Han LJ, Wen YF, Yuan L, Guo SS, Liu LT, Liu SL, Tang QN, Liang YJ, Li XY, Lin C, Guo L, Mai HQ, Tang LQ. Xiao BB, et al. Among authors: lv xf. Eur Radiol. 2021 Jul;31(7):5222-5233. doi: 10.1007/s00330-020-07478-1. Epub 2021 Jan 8. Eur Radiol. 2021. PMID: 33416977 Free PMC article.
Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial.
Luo DH, Li XY, Guo SS, Guo WP, Liu LT, Mo HY, Guo L, Lv XF, Liu LZ, Li JB, Liu Q, Wang P, Sun XS, Liu SL, Chen QY, Tang LQ, Mai HQ. Luo DH, et al. Among authors: lv xf. Lancet Reg Health West Pac. 2023 Aug 31;40:100895. doi: 10.1016/j.lanwpc.2023.100895. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 37691885 Free PMC article.
Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
Guo SS, Yang JH, Sun XS, Liu LZ, Yang ZC, Liu LT, Liu SL, Li XY, Lv XF, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Sun R, Yang Q, Liang YJ, Jia GD, Zhao C, Chen QY, Tang LQ, Mai HQ. Guo SS, et al. Among authors: lv xf. Eur J Cancer. 2023 Nov;194:113336. doi: 10.1016/j.ejca.2023.113336. Epub 2023 Sep 9. Eur J Cancer. 2023. PMID: 37801967 Clinical Trial.
164 results